PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

Study finds substantial concordance between PSMA-PET and conventional imaging for primary prostate cancer staging. Using prostate-specific membrane antigen positron emission tomography (PSMA-PET) for ...

Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT was superior to multiparametric MRI for primary locoregional staging of prostate cancer, according to results from a phase II ...

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer. The FDA has approved ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U ...

Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse ...

PSMA-PET scans detected metastatic disease in 46% of patients, indicating understaging by conventional imaging in high-risk nonmetastatic hormone-sensitive prostate cancer. The study involved 182 ...

New PSMA PET/CT can detect signs of prostate cancer within elderly patients without the need of a biopsy. PSMA PET/CT scans can detect signs of prostate cancer in elderly patients without the need of ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...